摘要
目的比较三种药物氧氟沙星、左氧氟沙星及莫西沙星治疗呼吸道感染的成本-效果,以指导临床合理用药。方法选择2014年6月至2015年12月期间进入我院呼吸内科进行治疗的呼吸道感染患者216例,随机的分为三组,分别为氧氟沙星组、左氧氟沙星组和莫西沙星组,每组患者72例,三组患者分别采用氧氟沙星、左氧氟沙星及莫西沙星进行治疗,比较三组患者治疗后的效果、成本效果比以及敏感度。结果左氧氟沙星组患者的总有效率为91.67%,显著高于氧氟沙星组患者的80.55%和莫西沙星组患者的86.11%,P<0.05;左氧氟沙星组的治疗成本效果比与增量成本效果比最低,分别为5.59和2.88,显著低于氧氟沙星组和莫西沙星组,莫西沙星组最高,分别为11.33和89.21,P<0.05;敏感度比较中,左氧氟沙星组的治疗成本效果比与增量成本效果比最低,分别为2.45和2.88,低于氧氟沙星组和莫西沙星组,莫西沙星组最高,分别为9.63和75.83,P<0.05。结论三种治疗呼吸道感染的药物中,左氧氟沙星的治疗总有效率最高,成本最低,最经济。
Objective To evaluate cost and effectiveness of ofloxacin,levofloxacin and moxifloxacin for treatment of respiratory tract infections. Methods 216 cases of respiratory tract infections were selected during Jun 2014-Dec 2015 and divided into ofloxacin group（ 72 cases）,levofloxacin group（ 72 cases）,and moxifloxacin group（ 72 cases） randomly. Ofloxacin group received ofloxacin intravenously,levofloxacin group received levofloxacin intravenously,moxifloxacin group received moxifloxacin intravenously. Observed clinical efficacy,conducted cost-effectiveness analysis,and compared the sensitivity. Results The total effective rate was 91. 67% in levofloxacin group,significantly higher than 80. 55% in ofloxacin group and 86. 11% in moxifloxacin group. The lowest cost-effectiveness ratio and the incremental cost-effectiveness ratio were 5. 59 and 2. 88 in levofloxacin group,and the highest cost-effectiveness ratio and the incremental cost-effectiveness ratio were 11. 33 and 89. 21,P〈0. 05. In the sensitivity analysis,the lowest cost-effectiveness ratio and the incremental costeffectiveness ratio were 2. 45 and 2. 88 in levofloxacin group,and the highest cost-effectiveness ratio and the incremental cost-effectiveness ratio were 9. 63 and 75. 83,P〈0. 05. Conclusion Levofloxacin has the highest clinically effective rate and the lowest cost,which is more rational antibacterial agent.
出处
《辽宁医学杂志》
2016年第5期6-8,共3页
Medical Journal of Liaoning
